Adma Biologics (ADMA) Cash from Operations Growth (1y) (2012 - 2025)
Adma Biologics (ADMA) Cash from Operations Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 158.60% |
| 10 | Adma Biologics | 2.02 Bn | 1.93 Bn | 88.82 Mn | -29.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.03% |
| Sep 30, 2025 | -46.89% |
| Jun 30, 2025 | -53.69% |
| Mar 31, 2025 | -787.06% |
| Dec 31, 2024 | 185.37% |
| Sep 30, 2024 | 108.83% |
| Jun 30, 2024 | 853.36% |
| Mar 31, 2024 | 84.94% |
| Dec 31, 2023 | 338.47% |
| Sep 30, 2023 | 190.22% |
| Jun 30, 2023 | 52.78% |
| Mar 31, 2023 | 43.40% |
| Dec 31, 2022 | 77.95% |
| Sep 30, 2022 | 0.95% |
| Jun 30, 2022 | 60.23% |
| Mar 31, 2022 | 21.72% |
| Dec 31, 2021 | -3.87% |
| Sep 30, 2021 | 43.77% |
| Jun 30, 2021 | -51.58% |
| Mar 31, 2021 | -34.82% |